Proof-of-concept Study for BIVV020 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- Part A: Efficacy of BIVV020 across three subpopulations of CIDP patients: standard of
care (SOC)-Treated, SOC-Refractory and SOC-Naive
- Part B:Long-term safety and tolerability of BIVV020 in CIDP
Secondary Objective:
-Part A: Safety and tolerability of BIVV020 in CIDP
- Immunogenicity of BIVV020
- Efficacy of BIVV020 with overlapping SOC (SOC-Treated group)
- Part B:
Durability of efficacy during long-term treatment with BIVV020 in CIDP Long-term
immunogenicity of BIVV020 in CIDP